» Articles » PMID: 18521690

Revisiting the Duration of Vasomotor Symptoms of Menopause: a Meta-analysis

Overview
Publisher Springer
Specialty General Medicine
Date 2008 Jun 4
PMID 18521690
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Treatment decisions about menopause are predicated on a transient duration of vasomotor symptoms. However, evidence supporting a specific duration is weak.

Objective: To estimate the natural progression of vasomotor symptoms during the menopause transition by systematically compiling available evidence using meta-analytic techniques.

Data Sources: We searched MEDLINE, hand searched secondary references in relevant studies, book chapters, and review papers, and contacted investigators about relevant published research.

Review Methods: English language, population-based studies reporting vasomotor symptom prevalence among women in menopausal transition in time intervals based on years to or from final menstrual period were included. Two reviewers independently assessed eligibility and quality of studies and extracted data for vasomotor symptom prevalence.

Results: The analyses included 10 studies (2 longitudinal, 8 cross sectional) with 35,445 participants. The percentage of women experiencing symptoms increased sharply in the 2 years before final menstrual period, peaked 1 year after final menstrual period, and did not return to premenopausal levels until about 8 years after final menstrual period. Nearly 50% of all women reported vasomotor symptoms 4 years after final menstrual period, and 10% of all women reported symptoms as far as 12 years after final menstrual period. When data were examined according to symptom severity ('any' vs. 'bothersome'), bothersome symptoms peaked about 1 year earlier and declined more rapidly than symptoms of any severity level.

Conclusions: Our findings suggest a median symptom duration of about 4 years among symptomatic women. A longer symptom duration may affect treatment decisions and clinical guidelines. Further prospective, longitudinal studies of menopausal symptoms should be conducted to confirm these results.

Citing Articles

The association of vasomotor symptoms with fracture risk and bone mineral density in postmenopausal women: a systematic review and meta-analysis of observational studies.

Anagnostis P, Lallas K, Pappa A, Avgeris G, Beta K, Damakis D Osteoporos Int. 2024; 35(8):1329-1336.

PMID: 38563960 PMC: 11281950. DOI: 10.1007/s00198-024-07075-8.


The influence of habitual physical activity and sedentary behavior on objective and subjective hot flashes at midlife.

Witkowski S, White Q, Shreyer S, Brown D, Sievert L Menopause. 2024; 31(5):381-389.

PMID: 38530999 PMC: 11052676. DOI: 10.1097/GME.0000000000002341.


Electroacupuncture for hot flashes in early postmenopause: A study protocol for a randomized sham-controlled trial.

Wang H, Yu X, Hu J, Chen J, Mei Y, Chen Y Contemp Clin Trials Commun. 2023; 36:101234.

PMID: 38047141 PMC: 10689878. DOI: 10.1016/j.conctc.2023.101234.


Insights into the genetics of menopausal vasomotor symptoms: genome-wide analyses of routinely-collected primary care health records.

Ruth K, Beaumont R, Locke J, Tyrrell J, Crandall C, Hawkes G BMC Med Genomics. 2023; 16(1):231.

PMID: 37784116 PMC: 10546673. DOI: 10.1186/s12920-023-01658-w.


The menopausal transition period and cardiovascular risk.

Mehta J, Manson J Nat Rev Cardiol. 2023; 21(3):203-211.

PMID: 37752349 DOI: 10.1038/s41569-023-00926-7.


References
1.
McKinlay S, Jefferys M . The menopausal syndrome. Br J Prev Soc Med. 1974; 28(2):108-15. PMC: 478848. DOI: 10.1136/jech.28.2.108. View

2.
. Executive summary. Hormone therapy. Obstet Gynecol. 2004; 104(4 Suppl):1S-4S. DOI: 10.1097/01.AOG.0000138807.32767.32. View

3.
. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004; 11(1):11-33. DOI: 10.1097/01.GME.0000108177.85442.71. View

4.
Avis N, Crawford S, McKinlay S . Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health. 1997; 3(2):103-20. View

5.
Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-77. DOI: 10.1001/jama.297.13.1465. View